دوره 1، شماره 1 - ( 10-1385 )                   جلد 1 شماره 1 صفحات 16-21 | برگشت به فهرست نسخه ها


XML English Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Hamidi A, Jahanguiri B, Nasr Esfahani M, Dadfar M. Naltrexone in Obsessive-Compulsive Disorder: an Open- Label Trial. IJPBS. 2007; 1 (1) :16-21
URL: http://ijpbs.mazums.ac.ir/article-1-145-fa.html
Naltrexone in Obsessive-Compulsive Disorder: an Open- Label Trial. Iranian Journal of Psychiatry and Behavioral Sciences. 1385; 1 (1) :16-21

URL: http://ijpbs.mazums.ac.ir/article-1-145-fa.html


چکیده:   (16271 مشاهده)
Objective: In spite of introduction of novel drugs, Obsessive-Compulsive Disorder (OCD) has still found no suitable treatment. On the other hand, high rates of co-morbidity of OCD with bipolar spectrum disorders are increasingly recognized. Mood switching and development of rapid cycling with antidepressants are significant problems in these patients. From this viewpoint, introducing a non-antidepressant anti-OCD drug has great theoretical and clinical importance. In this open-label clinical trial we evaluated the effects of naltrexone on OCD symptoms.
Method: In this study, 23 OCD outpatients treated with a fixed dose of clomipramie, fluoxetine, or both, for at least 3 months before trial underwent treatment with naltrexone, 25 to 100 milligrams a day as adjunctive treatment. Change in symptoms was evaluated by Yale-Brown Obsessive-Compulsive Scale (YBOCS), Persian version, administered at baseline and at the end of the 2 months trial.
Results: Seven patients dropped out of the study before the end of the 2 months: 4 patients for non-response and 3 patients for intolerable side effects. Sixteen patients, 9 females and 7 males, completed the study. The most frequent co-morbid disorders found in these patients were bipolar spectrum disorders (68.7%). Non-parametric (Wilcoxon Signed Ranks Test) and parametric (paired t-test) analyses both showed significant reductions in YBOCS ratings after naltrexone treatment (P<0.001). Two patients remained symptom free over 6 months after discontinuation of all medications.
Conclusion: Although small sample size and open design of the trial make the results tentative, it appears that naltrexone may be effective on at least certain subgroups of OCD patients, especially those with both OCD and bipolar spectrum disorders. Long-term effects of the drug after discontinuation should be addressed in future double-blind studies.
متن کامل [PDF 95 kb]   (2109 دریافت)    
نوع مطالعه: پژوهشي | موضوع مقاله: روانپزشکی
دریافت: ۱۳۹۱/۳/۸ | پذیرش: ۱۳۹۲/۱۰/۱۶ | انتشار: ۱۳۹۲/۱۰/۱۶

ارسال نظر درباره این مقاله : نام کاربری یا پست الکترونیک شما:
کد امنیتی را در کادر بنویسید

کلیه حقوق این وب سایت متعلق به Iranian Journal of Psychiatry and Behavioral Sciences می باشد.

طراحی و برنامه نویسی : یکتاوب افزار شرق

© 2015 All Rights Reserved | Iranian Journal of Psychiatry and Behavioral Sciences

Designed & Developed by : Yektaweb